Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008

Timmers, Lonneke; Beckeringh, J. J.; Herk‐Sukel, Myrthe P. P. van; Boven, Epie; Hugtenburg, Jacqueline G.

doi:10.1002/pds.2225

Cited by 15 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Information on Oral Anticancer Agent Use C. C. L. M. Boons et al (Table 4). 1 Variables were dichotomized into most adverse quartile versus the other three quartiles (reference category). 2 Only patients on treatment (n = 130) were included in the regression analyses because quality of life was not assessed in patients off treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Significant relations are shown in bold (P < 0.05). Abbreviations: OACA, oral anticancer agent; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; Brief IPQ, Brief Illness Perception Questionnaire; BMQ-Specific, Beliefs about Medicines Questionnaire Specific; OR, odds ratio; 95% CI, 95% confidence interval 1. Variables were dichotomized into most adverse quartile versus the other three quartiles (reference category) 2.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Patient satisfaction with information on oral anticancer agent use

et al. 2017

Self Cite

View full text Add to dashboard Cite

Adequate information on oral anticancer agent (OACA) use is an essential element of optimal cancer care. The present study aimed to get insight into the experiences of patients with information on OACA treatment and their characteristics regarding information dissatisfaction. Patients of four Dutch university hospitals using OACA participated in this observational study and completed the Satisfaction with Information about Medicines Scale (SIMS), EORTC Quality of Life Questionnaire‐C30, Brief Illness Perception Questionnaire, and Beliefs about Medicines Questionnaire‐Specific. Logistic regression analyses were used to determine factors associated with dissatisfaction with information. Patients (n = 208) using capecitabine (35%), lenalidomide (15%), imatinib (14%), temozolomide (12%), sunitinib (11%), thalidomide (5%), dasatinib (4%), erlotinib (2%), and nilotinib (2%) participated. Information on the following SIMS‐items was inadequate: how OACA elicit their effect, how long it takes before treatment works, how to conclude that treatment is effective, the risk of side effects and its management, interference with sex life, drowsiness, interference with other medication and alcohol and what to do in case of a missed dose. Younger age, hematological malignancy, dyspnoea, positive perception of consequences of the cancer, low perception of treatment control, and indifferent attitude towards OACA were associated with dissatisfaction with information. In conclusion, a considerable number of patients would have appreciated receiving more information on specific issues relating to the consequences of OACA treatment such as the effects and side effects of OACA and the interference of treatment with various aspects of their daily life. Oncologists, hematologists, lung‐oncologists and pharmacists may reconsider the provision of information on OACA treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Patient satisfaction with information on oral anticancer agent use

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The study showed that the cost per member per month (PMPM) experienced a nearly threefold increase from 2002 to 2006 for small, self-insured employers. Timmers et al [14] examined the medication cost of oral anticancer agents in The Netherlands. They also found a rapid increase in the use and costs of oral anticancer drugs, reporting a 50-fold increase in the costs of oral anticancer agents from 2000 to 2008 in The Netherlands.…”

Section: Non-drug-specific Studiesmentioning

confidence: 99%

A review of economic impact of targeted oral anticancer medications

Shen¹,

Chien²,

Geynisman³

et al. 2013

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.

show abstract

“…The potentially serious cardiac side effects and cost of the treatment cannot be overlooked. A study conducted in the Netherlands analyzed the use and costs of oral anticancer agents between 2000 and 2008 and showed a 50-fold rise in costs of oral anticancer agents between 2000 and 2008; 67% of this rise was attributable to tyrosine kinase inhibitors (TKIs) 43. One of the most effective tyrosine kinase inhibitors, imatinib, has been evaluated in many pharmacoeconomic studies.…”

Section: The Ret Vegf-r and Egf-r Pathways In Mtcmentioning

confidence: 99%

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer

Degrauwe

Sosa

Roman

et al. 2012

Clin Med Insights Oncol

View full text Add to dashboard Cite

Medullary thyroid cancer (MTC) represents an aggressive form of thyroid malignancy. Some may occur spontaneously or can be associated with Multiple Endocrine Neoplasia syndromes, or Familial Medullary Thyroid Cancer syndrome. In these patients, the protooncogene RET (rearranged during transfection) is mutated. In patients who have unresectable or metastatic disease, the long term prognosis is poor. New treatments for this disease have focused on the use of targeted agents that inhibit the receptor tyrosine kinase of RET. One of these treatments, Vandetanib (Caprelsa, Astra Zeneca), recently has received approval from the Food and Drug Administration for the treatment of patients with progressive locally advanced and/or metastatic disease. This review highlights the studies that led to the drug’s approval, and discusses on the potential financial costs of treatment and side effects of this therapy. The main clinical studies evaluating Vandetanib for the treatment of other solid tumors will also be reviewed.

show abstract

Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008

Cited by 15 publications

References 34 publications

Patient satisfaction with information on oral anticancer agent use

Patient satisfaction with information on oral anticancer agent use

A review of economic impact of targeted oral anticancer medications

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer

Contact Info

Product

Resources

About